Li Mei, Zhong Kun, He Guifang, Yin Yu
Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, PR China.
Department of Pathology, NO.2 People' s Hospital of Fuyang City, Fuyang, Anhui, 236015, PR China.
Heliyon. 2024 Jul 26;10(15):e34864. doi: 10.1016/j.heliyon.2024.e34864. eCollection 2024 Aug 15.
To investigate changes in the immunophenotypes of androgen receptor (AR), prostate-specific antigen (PSA), synaptophysin (Syn), chromogranin A (CgA), p53 and Ki-67 after neoadjuvant endocrine therapy (NET) for prostate cancer (PCa) and to analyze their clinical significance.
Paired paraffin samples were collected from 40 PCa patients before and after NET, and immunohistochemistry were used to detect AR, PSA, Syn, CgA, p53 and Ki-67 expression. Based on The Cancer Genome Atlas (TCGA), Kaplan‒Meier survival curves were plotted for analysis of PSA and Ki-67 expression in relation to progression-free survival (PFS).
After NET, the mean scores for PSA and Ki-67 expression in PCa patients were lower than those before NET ( < 0.05), while the mean scores for Syn and CgA expression were higher than those before NET ( < 0.05). The mean Gleason score and WHO/ISUP (World Health Organization/International Society of Urological Pathology) grade after NET were lower than those before NET ( < 0.05). In PCa patients who had not yet received NET, PSA expression correlated positively with Gleason score and WHO/ISUP grade and negatively with Ki-67 expression ( < 0.05); p53 expression correlated negatively with Gleason score and WHO/ISUP grade ( < 0.05). TCGA showed that PFS was lower in PCa patients with high PSA and Ki-67 expression ( < 0.05).
PSA and Ki-67 protein expressions decreased significantly in PCa patients after NET and can be used as biological markers for prognostic assessment of PCa patients. NETs may induce a neuroendocrine (NE) phenotype in PCa. Monitoring the immunophenotypes of PCa patients after NET may inform assessment of efficacy and prognosis.
探讨前列腺癌（PCa）新辅助内分泌治疗（NET）后雄激素受体（AR）、前列腺特异性抗原（PSA）、突触素（Syn）、嗜铬粒蛋白A（CgA）、p53和Ki-67免疫表型的变化，并分析其临床意义。
收集40例PCa患者NET前后的配对石蜡样本，采用免疫组织化学法检测AR、PSA、Syn、CgA、p53和Ki-67的表达。基于癌症基因组图谱（TCGA），绘制Kaplan-Meier生存曲线，分析PSA和Ki-67表达与无进展生存期（PFS）的关系。
NET后，PCa患者PSA和Ki-67表达的平均得分低于NET前（<0.05），而Syn和CgA表达的平均得分高于NET前（<0.05）。NET后的平均Gleason评分和世界卫生组织/国际泌尿病理学会（WHO/ISUP）分级低于NET前（<0.05）。在尚未接受NET的PCa患者中，PSA表达与Gleason评分和WHO/ISUP分级呈正相关，与Ki-67表达呈负相关（<0.05）；p53表达与Gleason评分和WHO/ISUP分级呈负相关（<0.05）。TCGA显示，PSA和Ki-67高表达的PCa患者的PFS较低（<0.05）。
NET后PCa患者PSA和Ki-67蛋白表达显著降低，可作为PCa患者预后评估的生物学标志物。NET可能诱导PCa出现神经内分泌（NE）表型。监测NET后PCa患者的免疫表型可能有助于评估疗效和预后。
